COMPOUND PROFILE / SMALL MOLECULES
Rapamycin / Sirolimus.
Research draftRapamycin, also called sirolimus, is a prescription mTOR inhibitor.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Rapamycin, also called sirolimus, is a prescription mTOR inhibitor.
Mechanism
It affects mTOR signalling involved in immune function, cell growth and metabolism.
Human research
Approved medical uses and exploratory ageing studies address different populations. Human lifespan extension is not established.
Preclinical & other research
Animal ageing research provides an important hypothesis, not a proven human anti-ageing benefit.
Safety & unknowns
Infection risk, mouth ulcers, lipid changes and impaired wound healing are relevant.
Regulatory status
Approved indications are product-specific; off-label longevity use is not an approved indication.
Reported use & evidence
The supplied Rapamycin / Sirolimus profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.